(UTHR) United Therapeutics - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 24.754m USD | Total Return: 96.3% in 12m

Treating Pulmonary Arterial Hypertension
Total Rating 64
Safety 82
Buy Signal 0.12
Drug Manufacturers - Specialty & Generic
Industry Rotation: -1.9
Market Cap: 24.8B
Avg Turnover: 300M USD
ATR: 3.68%
Peers RS (IBD): 58.8
Risk 5d forecast
Volatility43.7%
Rel. Tail Risk-27.7%
Reward TTM
Sharpe Ratio1.59
Alpha73.46
Character TTM
Beta0.602
Beta Downside1.198
Drawdowns 3y
Max DD33.00%
CAGR/Max DD1.08
EPS (Earnings per Share) EPS (Earnings per Share) of UTHR over the last years for every Quarter: "2021-03": 0.61, "2021-06": 3.65, "2021-09": 3.42, "2021-12": 2.35, "2022-03": 5.03, "2022-06": 2.41, "2022-09": 4.91, "2022-12": 2.67, "2023-03": 4.86, "2023-06": 5.24, "2023-09": 5.38, "2023-12": 4.36, "2024-03": 6.17, "2024-06": 5.85, "2024-09": 6.39, "2024-12": 6.19, "2025-03": 6.6296, "2025-06": 6.41, "2025-09": 7.16, "2025-12": 7.7, "2026-03": 0,
EPS CAGR: -35.87%
EPS Trend: -2.2%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of UTHR over the last years for every Quarter: 2021-03: 379.1, 2021-06: 446.5, 2021-09: 444.7, 2021-12: 415.2, 2022-03: 461.9, 2022-06: 466.9, 2022-09: 516, 2022-12: 491.5, 2023-03: 506.9, 2023-06: 596.5, 2023-09: 609.4, 2023-12: 614.7, 2024-03: 677.7, 2024-06: 714.9, 2024-09: 748.9, 2024-12: 735.9, 2025-03: 794.4, 2025-06: 798.6, 2025-09: 799.5, 2025-12: 790.2, 2026-03: null,
Rev. CAGR: 15.39%
Rev. Trend: 97.0%
Last SUE: -0.62
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: UTHR United Therapeutics

United Therapeutics (NASDAQ: UTHR) is a biotechnology firm focused on developing and commercializing therapies for chronic, life-threatening conditions, primarily pulmonary arterial hypertension (PAH) and high-risk neuroblastoma. Its product portfolio includes inhaled and oral PAH treatments (Tyvaso DPI, Tyvaso solution, Remodulin, Orenitram, Adcirca), the monoclonal antibody Unituxin for neuroblastoma, and delivery systems such as the Remunity Pump. The company is also advancing pipeline candidates-including RemoPro, Ralinepag, the gene-therapy Aurora-GT, and nebulized Tyvaso for idiopathic pulmonary fibrosis-as well as xenograft organ-product platforms.

In its most recent fiscal year (FY 2025), United Therapeutics reported revenue of **$1.62 billion**, a **12% year-over-year increase**, driven by strong sales of Orenitram and the expanding Tyvaso line. The balance sheet remains robust with **$2.24 billion** in cash and short-term investments, supporting continued R&D spend of **$420 million**, which represents roughly **26%** of total revenue.

The PAH market is projected to grow at a **CAGR of 6.3%** through 2030, propelled by rising diagnosis rates and an aging population, while the broader biotech sector benefits from heightened investor appetite for specialty therapeutics and gene-therapy platforms-trends that align with United Therapeutics’ pipeline focus.

For deeper quantitative analysis, you might explore ValueRay’s data on UTHR.

Headlines to Watch Out For
  • Tyvaso sales growth drives pulmonary hypertension revenue
  • Remodulin and Orenitram sales contribute to PAH treatment
  • Pipeline advancements in xenotransplantation offer future growth
  • Regulatory approvals for new indications expand market reach
Piotroski VR‑10 (Strict) 6.0
Net Income: 1.33b TTM > 0 and > 6% of Revenue
FCF/TA: 0.13 > 0.02 and ΔFCF/TA -1.47 > 1.0
NWC/Revenue: 98.72% < 20% (prev 109.0%; Δ -10.26% < -1%)
CFO/TA 0.20 > 3% & CFO 1.56b > Net Income 1.33b
Net Debt (-1.56b) to EBITDA (1.81b): -0.86 < 3
Current Ratio: 6.60 > 1.5 & < 3
Outstanding Shares: last quarter (47.9m) vs 12m ago -1.64% < -2%
Gross Margin: 87.92% > 18% (prev 0.89%; Δ 8.70k% > 0.5%)
Asset Turnover: 41.76% > 50% (prev 39.07%; Δ 2.68% > 0%)
Interest Coverage Ratio: 88.27 > 6 (EBITDA TTM 1.81b / Interest Expense TTM 19.5m)
Altman Z'' 10.00
A: 0.40 (Total Current Assets 3.70b - Total Current Liabilities 560.6m) / Total Assets 7.88b
B: 1.09 (Retained Earnings 8.56b / Total Assets 7.88b)
C: 0.23 (EBIT TTM 1.72b / Avg Total Assets 7.62b)
D: 10.92 (Book Value of Equity 8.56b / Total Liabilities 783.8m)
Altman-Z'' Score: 19.14 = AAA
Beneish M -2.85
DSRI: 1.13 (Receivables 350.2m/279.3m, Revenue 3.18b/2.88b)
GMI: 1.01 (GM 87.92% / 89.24%)
AQI: 1.01 (AQ_t 0.31 / AQ_t-1 0.31)
SGI: 1.11 (Revenue 3.18b / 2.88b)
TATA: -0.03 (NI 1.33b - CFO 1.56b) / TA 7.88b)
Beneish M-Score: -2.85 (Cap -4..+1) = A
What is the price of UTHR shares? As of April 11, 2026, the stock is trading at USD 574.77 with a total of 378,974 shares traded.
Over the past week, the price has changed by +1.76%, over one month by +8.62%, over three months by +18.94% and over the past year by +96.31%.
Is UTHR a buy, sell or hold? United Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy UTHR.
  • StrongBuy: 6
  • Buy: 2
  • Hold: 6
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the UTHR price?
Analysts Target Price 630.7 9.7%
United Therapeutics (UTHR) - Fundamental Data Overview as of 06 April 2026
P/E Trailing = 20.2877
P/E Forward = 20.0401
P/S = 7.7778
P/B = 3.488
P/EG = 2.2505
Revenue TTM = 3.18b USD
EBIT TTM = 1.72b USD
EBITDA TTM = 1.81b USD
 Long Term Debt = unknown (none)
 Short Term Debt = unknown (none)
 Debt = unknown
 Net Debt = -1.56b USD (from netDebt column, last quarter)
Enterprise Value = 23.20b USD (24.75b + (null Debt) - CCE 1.56b)
Interest Coverage Ratio = 88.27 (Ebit TTM 1.72b / Interest Expense TTM 19.5m)
EV/FCF = 22.29x (Enterprise Value 23.20b / FCF TTM 1.04b)
FCF Yield = 4.49% (FCF TTM 1.04b / Enterprise Value 23.20b)
FCF Margin = 32.70% (FCF TTM 1.04b / Revenue TTM 3.18b)
Net Margin = 41.94% (Net Income TTM 1.33b / Revenue TTM 3.18b)
Gross Margin = 87.92% ((Revenue TTM 3.18b - Cost of Revenue TTM 384.4m) / Revenue TTM)
Gross Margin QoQ = 86.91% (prev 87.38%)
Tobins Q-Ratio = 2.94 (Enterprise Value 23.20b / Total Assets 7.88b)
 Interest Expense / Debt = unknown (Interest Expense 3.10m / Debt none)
 Taxrate = 17.95% (79.7m / 444.0m)
NOPAT = 1.41b (EBIT 1.72b * (1 - 17.95%))
Current Ratio = 6.60 (Total Current Assets 3.70b / Total Current Liabilities 560.6m)
 Debt / Equity = unknown (Debt none)
 Debt / EBITDA = -0.86 (Net Debt -1.56b / EBITDA 1.81b)
Debt / FCF = -1.50 (Net Debt -1.56b / FCF TTM 1.04b)
Total Stockholder Equity = 6.92b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.51% (Net Income 1.33b / Total Assets 7.88b)
RoE = 19.30% (Net Income TTM 1.33b / Total Stockholder Equity 6.92b)
RoCE = 23.52% (EBIT 1.72b / Capital Employed (Total Assets 7.88b - Current Liab 560.6m))
RoIC = 20.27% (NOPAT 1.41b / Invested Capital 6.97b)
WACC = 8.10% (E(24.75b)/V(24.75b) * Re(8.10%) + (debt-free company))
Discount Rate = 8.10% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.93%
[DCF] Terminal Value 79.79% ; FCFF base≈1.06b ; Y1≈1.19b ; Y5≈1.62b
[DCF] Fair Price = 667.8 (EV 27.71b - Net Debt -1.56b = Equity 29.27b / Shares 43.8m; r=8.10% [WACC]; 5y FCF grow 15.07% → 3.0% )
EPS Correlation: -2.15 | EPS CAGR: -35.87% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.03 | Revenue CAGR: 15.39% | SUE: -0.62 | # QB: 0
EPS next Quarter (2026-06-30): EPS=6.92 | Chg7d=-0.006 | Chg30d=-0.054 | Revisions Net=-3 | Analysts=11
EPS current Year (2026-12-31): EPS=28.21 | Chg7d=+0.209 | Chg30d=+0.025 | Revisions Net=-1 | Growth EPS=+1.3% | Growth Revenue=+4.4%
EPS next Year (2027-12-31): EPS=32.64 | Chg7d=+0.505 | Chg30d=+0.788 | Revisions Net=+7 | Growth EPS=+15.7% | Growth Revenue=+13.6%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.2% (Discount Rate 8.1% - Earnings Yield 4.9%)
[Growth] Growth Spread = -0.1% (Analyst 3.1% - Implied 3.2%)
External Resources
Dataroma Stockcircle